Activity of ceftaroline against pathogens associated with community-acquired pneumonia collected as part of the AWARE surveillance program, 2015-2016

Diagn Microbiol Infect Dis. 2019 Nov;95(3):114843. doi: 10.1016/j.diagmicrobio.2019.05.015. Epub 2019 May 30.


We report Assessing Worldwide Antimicrobial Resistance Evaluation (AWARE) program data for ceftaroline and comparators against isolates collected from identified lower respiratory tract sources in 2015 and 2016. MICs and susceptibility were determined using CLSI broth microdilution methodology and EUCAST breakpoints. Ceftaroline susceptibility among penicillin-resistant Streptococcus pneumoniae (MIC≥4 mg/L [nonmeningitis breakpoint]) ranged from 77.4% (Asia, 72/93) to 100% (Oceania, 16/16; Latin America, 15/15). Among MRSA, ceftaroline susceptibility ranged from 72.3% (Asia, 553/765) to 100% (Oceania, 39/39). Among β-lactamase-positive Haemophilus influenzae, ceftaroline susceptibility ranged from 69.2% (Asia, 36/52) to 100% (Oceania, 19/19). Susceptibility to ceftaroline against non-ESBL-producing Klebsiella pneumoniae was between 91.4% (Europe, 659/721) and 100% (Oceania, 55/55) and for Escherichia coli between 85.7% (Africa/Middle East, 42/49) and 92.1% (Oceania, 35/38). Ceftaroline is not active against ESBL producers. In this study, susceptibility to ceftaroline was high among the S. pneumoniae, Staphylococcus aureus, β-lactamase-negative H. influenzae, and ESBL-negative K. pneumoniae and E. coli collected.

Keywords: AWARE; Ceftaroline; Community-acquired pneumonia; Lower respiratory tract infection; Surveillance.

MeSH terms

  • Anti-Bacterial Agents / pharmacology*
  • Bacteria / drug effects*
  • Bacteria / isolation & purification*
  • Cephalosporins / pharmacology*
  • Community-Acquired Infections / microbiology
  • Drug Resistance, Bacterial / drug effects
  • Humans
  • Microbial Sensitivity Tests
  • Pneumonia / microbiology*
  • Public Health Surveillance


  • Anti-Bacterial Agents
  • Cephalosporins
  • T 91825